AGP Picks
View all

AGP Executive Report

Last update: 8 hours ago

Cell Therapy Deal: MaxCyte signed a technology license partnership with Genentech to use its ExPERT GTx platform across cell-engineering, analytics, and cGMP workflows. Bradykinin Angioedema Research: Pharvaris published a comprehensive review in Clinical Reviews in Allergy & Immunology backing bradykinin B2 receptor antagonism as a validated approach for bradykinin-mediated angioedema. AI in Pharma Adoption: A new report warns pharma’s AI spend is outpacing real use at key discovery steps, blaming fragmented data readiness and a “trust gap” between models and bench scientists. GLP-1 Coverage Pressure: Coverage gaps for employer benefits and Medicare are still shaping access to GLP-1s, with early Medicare pilot signals showing many older patients choosing injectables. Childhood Obesity Evidence: A meta-analysis suggests GLP-1 weight-loss injections may help some children with obesity, but only under specialist supervision due to side effects and unknown long-term safety. Clinical Trials Reform: FDA’s Project TrialBlazer aims to speed early trial timelines and bring more studies back to the U.S. Stroke Rehab Tech: Marengo Asia Hospitals launched rTMS to support stroke rehabilitation and neuroplasticity. Lung Cancer Screening Gap: A study finds only ~13% of lung cancer patients met low-dose CT screening criteria, highlighting eligibility and uptake barriers. Policy & Payments: A court ruled manufacturers can’t impose certain 340B rebate models without HHS approval; AHA also weighed in on Medicaid supplemental payments, provider tax rules, and price transparency bills. Tariffs Shake Pharma: Trump’s phased up-to-200% tariff plan for imported generic drugs is roiling markets and raising concerns about feasibility, supply-chain timing, and costs. PE-RADS Standardization: A new PE-RADS v2026 reporting framework is set to standardize CT/MR pulmonary embolism imaging communication across care teams. Neuro Workforce Concern (India): Experts warn rising neurological disorders are colliding with a shortage of neurologists, delaying diagnosis and treatment.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

AGP Wire

fallback image
8 hours ago

RN Enterprises acquires Helping Hands Home Healthcare to expand Florida care

AGP

fallback image
Jul. 7, 2026

Stellar Bridge Solutions launches consulting firm for smaller pharma companies

AGP

fallback image
10 hours ago

STK returns with AI-native smartphone for clinical trials

AGP

fallback image
Jul. 21, 2026

Pathology imaging systems market seen reaching $2.29 billion by 2030

AGP


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Man who quit his job, asked his brother to leave college, later built India’s 4th largest pharma company worth Rs 10000000000000, he is…, company name is…

Man who quit his job, asked his brother to leave college, later built India’s 4th largest pharma company worth Rs 10000000000000, he is…, company name is…

Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?

Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?

Will Trump’s 200% Generic Drug Tariff Plan Hurt India’s Pharma Industry? Why The Next Two Years Matter

Will Trump’s 200% Generic Drug Tariff Plan Hurt India’s Pharma Industry? Why The Next Two Years Matter

Trump targets generic drug makers: Announces up to 200% tariff on cheaper drug Imports; What it means for India’s pharma industry

Trump targets generic drug makers: Announces up to 200% tariff on cheaper drug Imports; What it means for India’s pharma industry

As featured in:

@ Journalists!

Join

No journalists yet — this is a new service area. Join today!

Journalists Wanted

fallback image
6 hours ago

RCP celebrates quality improvement, advocacy and collaboration during Pulmonary Rehabilitation Awareness Week 2026

Royal College of Physicians

fallback image
3 hours ago

Self Sterilizing Medical Devices Market Report Highlights Key Segments, Regional Trends And Major Competitors

EIN Presswire

fallback image
4 hours ago

ABL Diagnostics Selected by the Évry Commercial Court to Acquire TEXCELL’s Operations

EIN Presswire

fallback image
3 hours ago

Global Robotic Endoscopy Devices Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~10% by 2034 | DelveInsight

GlobeNewswire, Inc.

fallback image
12 hours ago

CMS issues proposed provider tax rule

American Hospital Association

More press releases

Video Stories

YouTube video thumbnail: The Truth About gut Health
Play
The Truth About gut Health
YouTube video thumbnail: The Impact of U.S. Service Member Injuries in the Middle East
Play
The Impact of U.S. Service Member Injuries in the Middle East
Affinity Group Publishing Logo Showcase
Discover Affinity Group Publishing
YouTube video thumbnail: What False Positive Cyclospora Test Means for Outbreak, According to Former FDA Medical Officer
Play
What False Positive Cyclospora Test Means for Outbreak, According to Former FDA Medical Officer
YouTube video thumbnail: Trump Plans 100% Tariff on Generic Drugs From 2028
Play
Trump Plans 100% Tariff on Generic Drugs From 2028

Video Title

Sign up for:

Medical Industry Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Medical Industry Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.